Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics cash
Cash and short-term investments held at the end of each period.
Myriad Genetics's cash was $115.20M at Jun 30, 2026. For fiscal 2025 it was $149.60M, up 33.7% from the year before. Over ten years it grew -2.2% a year on average. The highest annual figure on record is $488.38M in fiscal 2010.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.60M | +33.7% |
| FY2024 | Dec 31, 2024 | $111.90M | -20.6% |
| FY2023 | Dec 31, 2023 | $140.90M | -17.0% |
| FY2022 | Dec 31, 2022 | $169.70M | -33.4% |
| FY2020 | Jun 30, 2020 | $254.80M | +32.8% |
| FY2019 | Jun 30, 2019 | $191.80M | +6.2% |
| FY2018 | Jun 30, 2018 | $180.60M | +19.8% |
| FY2017 | Jun 30, 2017 | $150.70M | -5.2% |
| FY2016 | Jun 30, 2016 | $159.00M | +9.8% |
| FY2015 | Jun 30, 2015 | $144.80M | -22.3% |
| FY2014 | Jun 30, 2014 | $186.40M | -49.9% |
| FY2013 | Jun 30, 2013 | $372.34M | +9.3% |
| FY2012 | Jun 30, 2012 | $340.58M | -18.4% |
| FY2011 | Jun 30, 2011 | $417.31M | -14.6% |
| FY2010 | Jun 30, 2010 | $488.38M | +669.0% |
| FY2009 | Jun 30, 2009 | $63.51M | -73.3% |
| FY2008 | Jun 30, 2008 | $237.73M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $115.20M | +54.8% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $124.40M | +35.5% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $149.60M | +33.7% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $145.40M | +45.5% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $74.40M | -23.5% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $91.80M | -12.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $111.90M | -20.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $99.90M | +15.8% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $97.30M | -20.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $104.30M | +32.5% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $140.90M | -17.0% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $86.30M | -54.9% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $121.60M | -40.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $78.70M | -70.6% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $169.70M | -33.4% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $191.20M | +5.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $204.10M | +44.1% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $267.40M | +87.5% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $254.80M | +32.8% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $181.50M | +21.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $141.60M | -14.4% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $142.60M | -14.9% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $191.80M | +6.2% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $149.70M | -4.8% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $165.40M | +15.3% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $167.50M | +12.9% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $180.60M | +19.8% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $157.30M | -8.6% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $143.50M | -11.6% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $148.30M | -0.1% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $150.70M | -5.2% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $172.10M | -20.6% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $162.40M | -25.9% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $148.40M | -4.5% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $159.00M | +9.8% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $216.70M | +61.2% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $219.30M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $155.40M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $144.80M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $134.42M | – |
See a number that looks wrong?